Real Chemistry, a marketing and communications agency that works only for drug and healthcare companies, has launched a set of artificial intelligence tools called Anatomi. The firm is the largest independent agency of its kind, with about 2,400 staff and $560 million in revenue last year. The launch marks its 25th year.
First, the plain version of what the agency does. When a pharmaceutical company has a new medicine, it needs to explain it to doctors, patients, journalists and regulators, and to advertise it within strict rules. That work of getting a treatment to market is called commercialization. Real Chemistry handles it for its clients.
Anatomi is a bundle of AI tools built for that job. The agency says the name reflects a design like human anatomy, a connected system meant to grow over time. It draws on large language models, the technology behind chatbots, plus the agency's own data and outside sources, and stitches them together. The pitch is that these tools are tuned for healthcare, rather than being general-purpose AI pointed at a medical problem. Some can carry out tasks, not just answer questions.
What can it do? On the communications side, it analyses market trends, reports on media activity, prepares briefings for reporters and plans executive announcements. On the marketing side, it helps develop brand strategy, mines cultural trends, creates content and checks that advertising meets the US Food and Drug Administration's rules. In a field with strict rules, that last point matters, because a compliance slip can be costly.
The agency says all data is handled in a "highly controlled and compliant way," which here means kept private and within the law.
Why launch now? The timing is the interesting part. General tools such as ChatGPT are putting more of these capabilities within reach of companies themselves. A drug firm that once hired an agency for this work can now do some of it in-house. The rival group Omnicom has warned the trend could make agency services less appealing to some clients. Building specialist tools is one way for an agency to argue it still offers something the off-the-shelf products cannot.
Anatomi is not Real Chemistry's first move here. It follows a tool that reads FDA warning letters, a system for testing vaccine messaging, and a tie-up with Amazon Web Services to power the agency's advertising engine.
The wider point is simple. As AI spreads, the firms whose job was to know a complicated field are racing to prove they still add value on top of the machines. Real Chemistry's answer is to package its expertise as software, aimed at a corner of marketing where the rules are tight and mistakes are expensive.
